GALDY (Galderma Group AG) EBITDA: $1,136 Mil (TTM As of Dec. 2025)


GALDY Galderma Group AG GALDY
21 GF Score
Price $44.23
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG EBITDA?

Galderma Group AG GALDY -1.72% 21 EBITDA is $1,136 Mil as of Dec. 2025. GuruFocus rates GALDY with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Galderma Group AG's EBITDA for the six months ended in Dec. 2025 was $630 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $1,136 Mil.

During the past 12 months, the average EBITDA Growth Rate of Galderma Group AG was 5.90% per year. During the past 3 years, the average EBITDA Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 5 years, the highest 3-Year average EBITDA Growth Rate of Galderma Group AG was 20.80% per year. The lowest was 15.90% per year. And the median was 18.35% per year.

Galderma Group AG's EBITDA per Share for the six months ended in Dec. 2025 was $0.53. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.96.

During the past 12 months, the average EBITDA per Share Growth Rate of Galderma Group AG was 6.20% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 5 years, the highest 3-Year average EBITDA per Share Growth Rate of Galderma Group AG was 20.80% per year. The lowest was 16.00% per year. And the median was 18.40% per year.

Galderma Group AG  (OTCPK:GALDY) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Galderma Group AG EBITDA Related Terms


Galderma Group AG EBITDA Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG EBITDA Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
526.10 624.20 851.00 959.00 1,136.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Get a 7-Day Free Trial 438.00 455.00 504.00 506.00 630.00

GALDY vs ZTS, UTHR, VTRS: EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galderma Group AG EV-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's EV-to-EBITDA falls into.


GALDY
21GF Score
Galderma Group AG GALDY
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Galderma Group AG's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Galderma Group AG's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, Galderma Group AG's EBITDA was $1,136 Mil.

Galderma Group AG's EBITDA for the quarter that ended in Dec. 2025 is calculated as

Galderma Group AG's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, Galderma Group AG's EBITDA was $630 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,136 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $1,136 Mil mean?
Galderma Group AG (GALDY) has a EBITDA of $1,136 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Galderma Group AG.
Is Galderma Group AG's EBITDA too high?
Galderma Group AG's current EBITDA is $1,136 Mil. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EBITDA compare to ZTS and UTHR?
Galderma Group AG's EBITDA of $1,136 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Drug Manufacturers company?
A good EBITDA depends on the Drug Manufacturers industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Galderma Group AG. Galderma Group AG's current EBITDA is $1,136 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current EBITDA of $1,136 Mil. The current EBITDA is $1,136 Mil. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current EBITDA is $1,136 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score

Get the complete analysis for GALDY

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.23
Price